Prostate News and Research

RSS

PRSS3 enzyme linked to aggressive prostate cancer

Researchers at Mayo Clinic's campus in Florida have identified an enzyme specifically linked to aggressive prostate cancer, and have also developed a compound that inhibits the ability of this molecule to promote the metastatic spread of the cancer.

18 Dec 2012

Abiraterone improves outcomes for prostate cancer prior to chemo

Treatment with abiraterone acetate, an androgen biosynthesis inhibitor, may benefit patients with progressive metastatic castration-resistant prostate cancer who have not yet undergone chemotherapy, report researchers.

17 Dec 2012

Elekta receives clearance for Clarity 4D Monitoring software

Elekta has received 510(k) clearance for its Clarity 4D Monitoring software, enabling U.S. medical centers to implement this new way of reducing the uncertainty caused by prostate motion during radiation treatment.

From Elekta 17 Dec 2012

New report provides snapshot of Canada's cancer system

A comprehensive report released today by the Canadian Partnership Against Cancer provides a snapshot of how Canada's cancer system is performing in key areas from prevention through to patient experience and outcomes.

17 Dec 2012

New technique could help develop more-specific, cell-based immune therapies for cancer

A team led by Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at Memorial Sloan-Kettering Cancer Center, has shown for the first time the effectiveness of a new technique that could allow the development of more-specific, cell-based immune therapies for cancer.

17 Dec 2012

New diagnostic innovations could refine the way doctors detect prostate cancer

Despite the volume of prostate cancer tests and treatments, experts and their patients are continually challenged to predict the disease's course and apply the most appropriate treatment. Now, two new diagnostic innovations – the PCA3 urine test and a more targeted prostate biopsy technique - could refine the way doctors diagnose prostate cancer and, subsequently, the way patients elect to treat it.

15 Dec 2012

Bayer files radium-223 NDA with FDA for treatment of CRPC patients with bone metastases

Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for radium Ra 223 dichloride (radium-223), an investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.

15 Dec 2012

New finding likely to fuel cost-benefit debate over cancer care

A study published Thursday in the Journal of the National Cancer Institute concluded that proton-beam therapy provided no long-term benefit over traditional radiation despite far higher costs.

15 Dec 2012

Prostate cancer patients experience minimal relief from side effects following proton radiotherapy

Prostate cancer patients receiving the costly treatment known as proton radiotherapy experienced minimal relief from side effects such as incontinence and erectile dysfunction, compared to patients undergoing a standard radiation treatment called intensity modulated radiotherapy (IMRT), Yale School of Medicine researchers report in the Journal of the National Cancer Institute.

14 Dec 2012

EZH2 protein enables advanced prostate cancers to spread without stimulation by male hormones

Scientists at Dana-Farber Cancer Institute have discovered a molecular switch that enables advanced prostate cancers to spread without stimulation by male hormones, which normally are needed to spur the cancer's growth. They say the finding could lead to a new treatment for prostate cancers that are no longer controlled by hormone-blocking drugs.

14 Dec 2012

CRI, SU2C form Cancer Immunology Translational Research Dream Team

Stand Up To Cancer (SU2C) and the Cancer Research Institute (CRI) announce the formation of a Dream Team project dedicated to cancer immunology - "Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy."

13 Dec 2012

U-M devises new system to capture and study circulating tumor cells

A glass plate with a nanoscale roughness could be a simple way for scientists to capture and study the circulating tumor cells that carry cancer around the body through the bloodstream.

12 Dec 2012

Study identifies KNDy neurons as a likely control switch of hot flushes

Hot flushes affect millions of people, and not just women. Yet, it is still unclear what causes the episodes of temperature discomfort, often accompanied by profuse sweating.

12 Dec 2012

MR-Ultrasound fusion biopsy can diagnose prostate cancer

Ground-breaking research by a UCLA team of physicians and engineers demonstrates that prostate cancer can be diagnosed using image-guided targeted biopsy.

11 Dec 2012

Magnetic resonance ultrasound fusion biopsy may improve prostate cancer diagnosis

Diagnosis of prostate cancer remains imperfect. Current methods of prostate biopsy are limited by over detection of slow-growing tumors and under detection of clinically relevant cancers. Investigators at the University of California-Los Angeles Department of Urology have found that a new technique of targeted biopsy in a clinic setting, using local anesthesia, may improve diagnosis and aid in selecting which patients are suitable for active surveillance and which need focal therapy (noninvasive techniques for destroying small tumors within the prostate).

11 Dec 2012